Category Biodiversity/Genetic Resources/Biotech

UPOV Marks 50 Years; Breeders Seek More Enforcement, Civil Society Wants In

This week the International Union for the Protection of New Varieties of Plants (UPOV) is celebrating its 50th anniversary. The Union is often criticised by civil society as being opaque, but plant breeders seem reasonably content with the latest version of the convention. However, some breeders that do not rely on seeds to reproduce their plants are seeking a clarification in the convention to prevent illegal use of their protected varieties.

WIPO To Launch New Drug R&D Database For Neglected Disease Licences

The World Intellectual Property Organization, in conjunction with the World Health Organization, private sector and foundation partners, is preparing to launch a new voluntary database for the sharing of intellectual property for research and development on medicines, vaccines and diagnostics for neglected diseases, according to sources in Geneva.

EU High Court Bans Patents On Human Embryo Stem Cells For Commerce

The European Union high court today outlawed the patenting of human embryo stem cells for scientific research or commercial purposes. The decision has forced European courts to examine the “ethical boundaries of patenting,” said Greenpeace, which challenged a German patent in the case. While there are alternate methods for obtaining stem cells, the ruling will nevertheless affect some research, one patent lawyer said.

Unpunished Human Rights Violations Challenge Right To Food, Activists Say

Despite international frameworks and mechanisms to protect food security as a human right, a number of violations are committed in total impunity, according to the third edition of the "Right to Food and Nutrition Watch" issued today, this year with a focus on accountability issues.

With WTO Stalled, GI Industry Proponents Move To Create Their Own Register

An international private-sector network lobbying for the protection of geographical indications is set to establish a compilation of all GIs currently protected in the world in what could seem like a response to the repeated failure of governments to agree on the establishment of a GIs register at the World Trade Organization. The Organization for an International Geographical Indications Network (OriGIn), meeting for its fifth General Assembly, also voiced concerns about the lack of protection of GIs in cyberspace.

Nagoya Protocol On Biodiversity Benefit-Sharing Has 64 Signatories

The UN agreement struck last year to bolster access and benefit-sharing related to biodiversity has been gaining signatures rapidly and may on its way to an early approval, according to the UN Convention on Biological Diversity secretariat. However, while countries are signing, not one has yet had a chance to ratify it.

Talk Of Treaties, Revenue Increase, Development As WIPO Annual Assemblies Kick Off

The annual World Intellectual Property Organization meeting of member states kicked off yesterday with hope among participants that the next year could bring a return to positive revenues, a settling of internal dissension, and some of the first treaties at the UN agency in nearly 20 years.

Experts Still Divided On Influence Of IP On Biodiversity Conservation

While the global loss of biodiversity is widely recognised, the question of whether the influence of intellectual property rights on the protection of biodiversity is positive or negative does not achieve such consensus. A discussion among specialists on 14 September showed that clear evidence is lacking about the impact of IP rights. Some said the IP system as it stands might be ill-fitted to answer the needs of this particular field.

South Africa Conference On IP And Innovation

A conference being held in South Africa this week will address the sensitive topic of intellectual property and innovation in the developing country context. On hand will be a top team of developed country experts with a mix of Indian and Chinese specialists.

Myriad Outcome: Winds Shift Again For Gene Patenting In The US

In a long-awaited decision, a United States federal appeals court has decided that US companies can patent breast cancer genes, reversing a previous ruling. The decision was not unanimous, with one of the three judges dissenting. But despite the attention the case has received, the ruling may have little impact on the biotechnology industry, according to analysts.